| Literature DB >> 26867474 |
Hacer Akturk1, Murat Sutcu2, Ayper Somer2, Derya Aydın3, Rukiye Cihan4, Aslı Ozdemir4, Asuman Coban5, Zeynep Ince5, Agop Citak6, Nuran Salman2.
Abstract
BACKGROUND: Little is known about factors associated with carbapenem-resistant Klebsiella pneumoniae infections in pediatric patients, who are initally colonized with carbapenem-resistant Klebsiella pneumoniae.Entities:
Keywords: Carbapenem resistant Klebsiella pneumoniae; Colonization; Infection; Pediatric/Neonatal intensive care
Mesh:
Substances:
Year: 2016 PMID: 26867474 PMCID: PMC9427560 DOI: 10.1016/j.bjid.2015.12.004
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Fig. 1The percantage of CRKP-C and CRKP-I cases among all admitted patients to the pediatric intensive care unit from 2010 to 2014.
Fig. 2The percantage of CRKP-C and CRKP-I cases among all admitted patients to the neonatal intensive care unit from 2010 to 2014.
Clinical characteristics of patients with CRKP-C and CRKP-I.
| CRKP-C | CRKP-I | ||
|---|---|---|---|
| 48 (78.7) | 22 (91.7) | 0.15 | |
| Respiratory disease | 34 (55.7) | 11 (45.8) | 0.41 |
| Malignancy | 2 (3.3) | 2 (8.3) | 0.32 |
| Neurological disease | 15 (24.6) | 11 (45.8) | 0.05 |
| Metabolic disease | 4 (6.6) | 10 (41.7) | <0.001 |
| Immunosuppression | 28 (45.9) | 16 (66.7) | 0.08 |
| 9 (14.8) | 11 (45.8) | 0.002 | |
| 5 (8.2) | 5 (20.8) | 0.10 | |
| CVC | 48 (78.7) | 24 (100) | 0.14 |
| PEG | 5 (8.2) | 4 (16.7) | 0.25 |
| Intubation/MV | 48 (78.7) | 24 (100) | 0.14 |
| Urinary catheterization | 20 (32.8) | 16 (66.7) | 0.04 |
| Tracheostomy | 7 (11.5) | 12 (50) | <0.001 |
| Surgery | 21 (34.4) | 18 (75) | <0.001 |
| Renal replacement therapy | 6 (9.8) | 2 (8.3) | 0.81 |
| Thoracic tube drainage | 9 (14.8) | 3 (12.5) | 0.78 |
| Surgical drainage tube | 16 (26.2) | 5 (20.8) | 0.60 |
| TPN | 31 (50.8) | 9 (37.5) | 0.26 |
| Third generation cephalosporin | 29 (47.5) | 11 (45.8) | 0.88 |
| β-Lactam/lactamase combinations | 27 (44.2) | 16 (66.7) | 0.57 |
| Carbapenems | 32 (52.4) | 19 (79.1) | 0.02 |
| Glycopeptides | 45 (73.8) | 18 (75) | 0.90 |
| Aminoglycosides | 34 (55.7) | 18 (75) | 0.10 |
| Colistin | 4 (6.5) | 0 | 0.19 |
| Quinolones | 12 (19.6) | 7 (29.1) | 0.34 |
CRKP, carbapenem-resistant Klebsiella pneumoniae; CRKP-C, CRKP colonized patients who did not developed subsequent CRKP infection; CRKP-I, CRKP colonized patients who developed subsequent CRKP infection; CVC, central venous catheter, PEG, percutaneous gastroenterostomy; MV, mechanical ventilation; TPN, total parenteral nutrition; Tx, treatment.
Including asthma, cystic fibrosis, brochopulmonar dysplasia.
Including epilepsy, cerebral palsy, neurological sequelae of previous encephalitis. Including mitochondrial diseases, maple syrup urine disease, methylmalonic acidemia, lysinuric protein intolerance.
including chronic granulomatous disease, common variable immune deficiency, and secondary immune deficiency states like use of steroid, monoclonal antibody, and other immunosuppressive agents.
Multivariate analysis of risk factors for CRKP infection in patients colonized with CRKP.
| Variables | OR (95% CI) | |
|---|---|---|
| Underlying metabolic disease | 0.03 | 10.1 (2.7–37.2) |
| Surgery | 0.02 | 7.4 (1.9–28.5) |
| Previous carbapenem use | 0.01 | 10.1 (2.2–40.1) |
| Neutropenia | 0.02 | 13.8 (3.1–61.0) |
CRKP, carbapenem resistant Klebsiella pneumonia.